Skip to content

US · KMTS · MEDICAL - INSTRUMENTS & SUPPLIES

Kestra Medical Technologies, Ltd. (KMTS) intrinsic value and stock valuation

$25.10as of 2026-11-21 · Mkt cap 1.47B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kestra Medical Technologies, Ltd. DCF and intrinsic value

InvestorsCraft values KMTS with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from KMTS’s statements →

Kestra Medical Technologies, Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Kirkland, WA 98033 kestramedical.com

How the business is doing

Fiscal 2023–2026, USD

Revenue
$95.1M
20232026
Net income
-$-131.61M
20232026
Free cash flow
-$-116.59M
20202026
Total equity
$259.7M+132% 5y CAGRd
20202026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2023–2026, USD
20262025202420232021
Revenue$95.1M$59.8M$27.8M$7.63M—
Operating income-$-134.74M-$-106.38M-$-85.06M-$-80.42M—
Net income-$-131.61M-$-113.81M-$-94.12M-$-84.24M—
EPSd-$-2.25M-$-2.3M-$-1.9M-$-1.7M—
Operating cash flow-$-81.7M-$-77.61M-$-72.23M-$-69.64M-$-29.89M
Capital expenditure-$-34.89M-$-23.59M-$-12.51M-$-15.46M-$-340K
Free cash flow-$-116.59M-$-101.2M-$-84.75M-$-85.1M-$-30.23M
Total assets$358.5M$295.7M$46M$38.7M$30.5M
Total debt$46.8M$44.3M$45.2M$39.1M$22.9M
Net debt-$-52.92M-$-193.28M$36.9M$24.3M-$-1.49M
Total equity$259.7M$205.4M-$-209.38M-$-117.58M$1.77M
Cash and short-term investments$196.4M$237.6M$8.25M$14.8M$24.3M
Income statement
2026202520242023
Revenue$95.1M$59.8M$27.8M$7.63M
Cost of revenue$46.3M$35.6M$27.5M$18.3M
Gross profit$48.9M$24.2M$360K-$-10.65M
Research and development expenses$19.5M$15.7M$15.5M$15.8M
Selling, general and administrative expenses$164.1M$114.9M$69.9M$54M
Other expenses$0.00$0.00$0.00$0.00
Operating expenses$183.6M$130.6M$85.4M$69.8M
Cost and expenses$229.9M$166.2M$112.9M$88.1M
Interest income$8.35M$3.2M$0.00$0.00
Interest expense$7.55M$7.73M$6.23M$5.63M
Depreciation and amortization-$-4.4M$7.97M$11.6M$4.86M
Ebitda-$-150.04M-$-97.98M-$-76.31M-$-73.74M
Operating income-$-134.74M-$-106.38M-$-85.06M-$-80.42M
Total other income/expenses, net$3.42M-$-7.3M-$-9.03M-$-3.8M
Income before tax-$-131.32M-$-113.68M-$-94.1M-$-84.22M
Income tax expense$290K$140K$20K$10K
Net income-$-131.61M-$-113.81M-$-94.12M-$-84.24M
Weighted average shares outstanding$58.4M$49.5M$49.5M$49.5M
Weighted average diluted shares outstanding$58.4M$49.5M$49.5M$49.5M
Balance sheet
20262025202420232021
Cash and short-term investments$196.4M$237.6M$8.25M$14.8M$24.3M
Net receivables$14.5M$8.08M$2M$2.11M$0.00
Inventory$6.71M$6.57M$3.29M$2.11M$0.00
Total current assets$222.4M$255.3M$14.9M$18.4M$26.2M
Property, plant and equipment, net$62.5M$36.9M$28.4M$16.7M$3.08M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$65.8M$0.00$0.00$0.00$0.00
Total non-current assets$136.1M$40.4M$31M$20.2M$4.33M
Total assets$358.5M$295.7M$46M$38.7M$30.5M
Accounts payable$27.3M$24M$23.9M$6.16M$1.7M
Short-term debt$30K$370K$0.00$21.8M$1.06M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$50.4M$38M$33M$36.7M$6.61M
Long-term debt$46.8M$44.1M$45.2M$17.3M$21.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$48.4M$52.4M$222.4M$119.5M$22.2M
Capital lease obligations$4.11M$3.21M$2.63M$1.37M$2.61M
Total liabilities$98.8M$90.3M$255.3M$156.2M$28.8M
Common stock$58.4M$51.4M$0.00$0.00$0.00
Retained earnings-$-651.86M-$-520.25M-$-406.44M-$-312.31M-$-170.08M
Accumulated other comprehensive income (loss)-$-220K$0.00$0.00$0.00$0.00
Total equity$259.7M$205.4M-$-209.38M-$-117.58M$1.77M
Total investments$162.5M$0.00$0.00$0.00$0.00
Total debt$46.8M$44.3M$45.2M$39.1M$22.9M
Net debt-$-52.92M-$-193.28M$36.9M$24.3M-$-1.49M
Cash flow statement
20262025202420232021
Net income-$-131.61M-$-113.81M-$-94.12M-$-84.24M-$-34.1M
Depreciation and amortization$8.71M$7.97M$11.6M$4.86M$420K
Stock-based compensation$33.6M$24.3M$1.49M$1.21M$1.86M
Change in working capital-$-690K-$-6.2M$4.39M$1.3M-$-20K
Accounts receivable-$-9.06M-$-8.78M-$-2M$0.00$0.00
Inventory-$-460K-$-3.44M-$-1.18M-$-730K$0.00
Accounts payable$4.3M$2.84M$7.34M$2.14M-$-130K
Net cash provided by operating activities-$-81.7M-$-77.61M-$-72.23M-$-69.64M-$-29.89M
Investments in property, plant and equipment-$-34.89M-$-23.59M-$-12.51M-$-15.46M-$-340K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-203.28M-$-23.31M-$-12.23M-$-15.46M-$-330K
Common stock issued$149.3M$215.8M$0.00$102.1M$0.00
Common stock repurchased-$-2.79M$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-1.65M-$-800K-$-670K-$-190K
Net cash used for financing activities$147.1M$330.3M$77.7M$96.1M$48.8M
Net change in cash-$-137.88M$229.4M-$-6.74M$11M$18.6M
Cash at end of period$100M$237.9M$8.58M$15.3M$24.9M
Operating cash flow-$-81.7M-$-77.61M-$-72.23M-$-69.64M-$-29.89M
Capital expenditure-$-34.89M-$-23.59M-$-12.51M-$-15.46M-$-340K
Free cash flow-$-116.59M-$-101.2M-$-84.75M-$-85.1M-$-30.23M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kestra Medical Technologies, Ltd.

        Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.

        CEO
        Brian Webster
        Employees
        330
        Beta
        0.58

        Explore

        Frequently asked questions

        What is the intrinsic value of Kestra Medical Technologies, Ltd. (KMTS)?

        Kestra Medical Technologies, Ltd. (KMTS) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is KMTS undervalued?

        KMTS trades at a price of $25.10 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.